LASSBio-1632

LASSBio-1632

• CAS Number: 3029936-02-2
• UNSPSC Description: LASSBio-1632 is a new anti-asthmatic lead candidate associated with selective inhibition of PDE4A and PDE4D isoenzymes and blockade of airway hyper-reactivity (AHR) and TNF-α production in the lung tissue. LASSBio-1632 (7j) displays high experimental BBB permeability across BBB through passive diffusion[1].
• Target Antigen: Phosphodiesterase (PDE)
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Applications: COVID-19-immunoregulation
• Field of Research: Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/lassbio-1632.html
• Solubility: 10 mM in DMSO
• Smiles: CC1=CC2=C(C=C1S(N(/N=C/C3=CC=C(C(OC)=C3)OC)C)(=O)=O)OCO2
• Molecular Weight: 392.43
• References & Citations: [1]Isabelle Karine da Costa Nunes, et al. Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies. Eur J Med Chem. 2020 Jul 18;204:112492.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported